KaliVir Immunotherapeutics
↗Pittsburgh, Pennsylvania, USA
KaliVir Immunotherapeutics is a clinical-stage biopharmaceutical company pioneering systemically deliverable oncolytic virus immunotherapies that harness vaccinia virus technology to treat cancer. Founded in 2019 and headquartered in Pittsburgh, PA, the company developed the proprietary Vaccinia Enhanced Template (VET™) platform, which enables potent novel oncolytic vaccinia viruses optimized for intravenous delivery with enhanced tumor selectivity and immune activation. The company leverages the unique ability of oncolytic viruses to replicate selectively in and kill cancer cells while simultaneously triggering anti-tumor immunity through engineered transgene payloads including IL-12 and TGF-beta inhibitors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$15M
Investors:Premier Partners LLC (Lead), ARCH Venture Partners, Company K Partners, Quad Investment Management
PIPELINE
Stage:Phase 1/1b Clinical
Lead Drug Stage:Phase 1/1b
Modalities:Oncolytic Virus, Vaccinia Virus Platform, Transgene Expression, Immunotherapy Combination
Active Trials:2
Trial Phases:Phase 1: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Astellas Pharma (Worldwide exclusive licensing VET2-L2/ASP1012), Roche (Global exclusive licensing + clinical collaboration for VET3-TGI + Tecentriq)
COMPETITION
Position:Emerging
Competitors:Replimune (RP1), Targovax/Oncos Therapeutics (ONCOS-102), Turnstone Biologics (Maraba virus), SillaJen Biotherapeutics, Oncolytics Biotech (REOLYSIN), Genelux Corporation (Olvi-Vec), Candel Therapeutics, CG Oncology +3 more
LEADERSHIP
Key Executives:
Helena Chaye - Chief Executive Officer
Stephen Thorne - Chief Scientific Officer & Co-Founder
Jon Wigginton, M.D. - Chief Medical Officer
Schond Greenway - Chief Financial Officer
Scientific Founders:Stephen Thorne (Co-Founder, CSO)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of KaliVir Immunotherapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with KaliVir Immunotherapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.